Better predict drug's effects on human Body

New microfluidic technology, alternative to animal experimentations

cherry-biotech-chip (Mobile) (1)

Main Features

PDMS free

The only commercial MPS PDMS free device with no bias in toxicology and efficacy studies

Incubator free

Direct integration in existing analysis workflow, without disruption of the culture conditions

Pré-clinical, 3D Culture & In Vitro Tox
Compatible with culture standard

From 6 to 24 well allowing a direct transfer of the culture protocol

Vascularized 3D biological model

Physiological maintenance of a differentiated endothelium with an organ stroma >5 days

Discover the Applications of Cubix

Our Experience

Our mission is to develop the most advanced technological platform for predicting the impact of molecules (drug, endocrine disruptor, cosmetic, etc.) on the human body to better treat pathologies (orphan diseases, cancer, bacterial resistance, virus). Moreover, This platform is an alternative to use less animals model by combining new microfluidic technology , artificial intelligence and most advanced imaging techniques.


We Are Here For You

Projects - 15
Partners - 150
Beta testers - 5

Cubix for Pharmaceautical and Biotech Companies

  • Benefits: Lower false positive drug candidate in preclinical phases, accelerate the drug development process, leading to drastic cost reduction
  • How?:  Obtain a functional 3D vascularized adipose tissue  in medium-throughput, for a hit to lead and lead characterization

Cubix for Academic and Translational Researchers

  • Benefits: New fundamental discovery leading to higher publications impact and increase Shanghai ranking
  • How?: Obtain a functional 3D vascularized adipose tissue long term (> 2weeks) for new molecular target identification and mechanism of action deciphering

Diabetes Knowlegde Centre

Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control Guidance for Industry
The International Diabetes Federation (IDF) is an umbrella organization of over 230 national diabetes associations in 170 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk
Understanding medicine -Type 2 diabetes
World Health Organization Diabetes Fact Sheet
With diabetes, knowledge is power. Explore this collection of articles created for people with diabetes or who are at risk for diabetes, and their families and friends.
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU). It began operating in 1995. The Agency is responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.